Navigation Links
Warner Chilcott Announces Secondary Equity Offering
Date:3/8/2011

DUBLIN, March 8, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today a secondary offering of 25 million of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering pursuant to an existing agreement.

Goldman, Sachs & Co., J.P. Morgan, Morgan Stanley, BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are joint book-running managers for the offering. The co-managers of the offering are Citi, Deutsche Bank Securities and UBS Investment Bank.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be a sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made by means of a prospectus supplement and the accompanying prospectus only. Copies of the prospectus supplement and accompanying prospectus can be obtained by contacting Goldman, Sachs & Co., at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: J.P. Morgan Securities LLC or by telephone at (866) 803-9204, and Morgan Stanley &
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Warner Chilcott to Present at the Goldman Sachs Leveraged Finance Healthcare Conference
2. Warner Chilcott Seeks to Refinance its Existing Credit Agreement
3. Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2010
4. Warner Chilcott to Present at the Citi 2011 Global Health Care Conference
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
6. Warner Chilcott to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
8. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
9. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
10. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
11. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently ... need to urgently address this issue has been emphasized by ... , "Medical device alarm safety in hospitals." According to The ... June 2012, there were 98 alarm related events reported, of ... , 13 resulted in permanent loss of function (13%) ...
(Date:6/19/2013)... Calif. , June 19, 2013  Finesse ... solutions for life sciences process applications, announced the ... bioreactors for upstream cell culture and fermentation.  The ... new product family of Finesse bioreactors and are ... cGMP applications.  They are fully compatible with all ...
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... June 18 Watson Pharmaceuticals, Inc. (NYSE: ... Watson management will provide an overview and update of the ... on Wednesday, June 23, 2010 at 11:15am ... . The presentation will be webcast live and can be ...
... , RESEARCH TRIANGLE PARK, N.C. , June 18 ... of Talecris Biotherapeutics (Nasdaq: TLCR ), received the Ernst ... health sciences category in the Carolinas at a ceremony last ... awards program recognizes entrepreneurs who demonstrate extraordinary success in the ...
Cached Medicine Technology:Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference 2Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients 2
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal ... moderate sedation, a patient’s breathing depth and rate decrease. ... latest to update its guidelines to require etCO2 monitoring, ... effort to increase safety in procedures. This amendment to ... into effect July 1. , The Oregon Board ...
(Date:6/19/2013)... June 19, 2013 Alternatives, a revolutionary ... patients to quit using drugs while allowing them to ... the founders of Alternatives, believe that abstinence-only approaches force ... enter treatment and that this approach hurts instead of ... in the United States need treatment for addiction but ...
(Date:6/19/2013)... 2013 Amerinet, Inc, a leading ... Technologies to help Pacific Medical Centers implement a ... more than 17 percent over the organization’s previous ... “Driving economies of scale and process standardization are ... facing multi-site providers,” said Shawn Padilla, director of ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... 2013 Imprivata ®, a leading ... that Imprivata OneSign ® leads the single sign-on ... Review: Software & Services report . CIOs and other ... the superior performance of its products and the quality ... that Imprivata is integral to their long-term healthcare IT ...
Breaking Medicine News(10 mins):Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... improve survival for out-of-hospital cardiac arrest, an analysis of data ... not result in an improved rate of survival, according to ... . The study is being released early online because it ... Use of automated external defibrillators (AEDs) has been proposed ...
... blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using ... heart failure or cardiovascular death in older adults, according to ... of JAMA . The study is being released early ... Association,s annual meeting. "Older adults comprise the majority of ...
... disease is widely believed to be caused by the gradual accumulation ... cells. Amyloid beta peptide is formed from a protein known as ... a key area of study for the disease does ... findings, published in the Journal of Biological Chemistry , show ...
... MONDAY, Nov. 15 (HealthDay News) -- Could cholesterol deposits ... risk? A preliminary Danish study suggests that the ... attack, arterial disease and early death. Half of ... actually have normal cholesterol levels. The research team therefore ...
... , MONDAY, Nov. 15 (HealthDay News) -- Omega-3 fatty acid ... type of irregular heartbeat that can cause stroke, new research ... work for most patients with AF [atrial fibrillation]," said Dr. ... the Dec. 1 issue of the Journal of the ...
... , SUNDAY, Nov. 14 (HealthDay News) -- As ... brain alter how they view themselves and others, a ... for introspection, researchers say. Georgetown University Medical Center ... the five scattered brain regions that comprise what,s known ...
Cached Medicine News:Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 2Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 3Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 2Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Cholesterol on Eyelids Might Point to Heart Risk 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 3Health News:Brain Organizes Itself for Introspection as Children Age: Study 2
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: